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Summary
Hormone 1α,25(OH)2-vitamin D3 (1,25D) is considered a bone
anabolic hormone. It increases bone matrix production and
mineralization via the nuclear vitamin D receptor (VDR), which
is abundantly expressed in osteoblasts. In addition, 1,25D ex-
erts rapid, non-genomic actions that do not involve gene
transactivation (1). These include: 1) activation of signal trans-
duction pathways, 2) cytoplasmic Ca2+ increase, and 3) ion
channel potentiation. While genomic mechanisms have been
extensively studied, the signaling involved in non-genomic,
membrane-initiated 1,25D actions is less well understood.
Moreover, the physiological significance of 1,25D non-genom-
ic effects in osteoblasts and its contribution to bone formation
is a field relatively unexplored. Recently we demonstrated, for
the first time in single live osteoblasts, a rapid (1-5 min) 1,25D-
induced increase of chloride currents at depolarizing poten-
tials (2, 3). This voltage-gated Cl- channel is selectively poten-
tiated by 1,25D (0.5-50 nM) in osteoblasts expressing a func-
tional VDR (4). We showed that this 1,25D-induced Cl- current
develops simultaneously with activation of exocytosis in sin-
gle osteoblasts (5). In addition, nanomolar concentrations of
1,25D activate L-type calcium channels at low depolarizing po-
tentials. These contribute to a rapid increase in cytoplasmic
Ca2+ concentration promoted by the hormone. The purpose of
this paper is to overview the current understanding on molec-
ular mechanisms of non-genomic 1,25D-mediated processes
of bone formation in osteoblasts. We found that 1,25D acting
at a membrane-associated VDR leads to a rapid, regulated ex-
ocytotic response that is coupled to Cl- and Ca2+ channel acti-
vation in osteoblasts and explains in part the anabolic effects
of the hormone in bone. 
KEY WORDS: osteoblasts, vitamin D3, rapid responses, ion channels, exo-
cytosis.
Introduction
Vitamin D was discovered originally as an antirachitic agent
(6). The development of new therapies for treatment and pre-
vention of bone mass loss depends on a full understanding of
the molecular mechanisms by which osteoblasts produce and
secrete bone, and how these processes are regulated by hor-
mones such as vitamin D. Here I review studies on non-ge-
nomic, membrane-initiated molecular mechanisms of secretion
of bone materials in single, live osteoblasts. We utilize tech-
niques of high spatial-temporal resolution applied to individual
osteoblasts in culture such as patch-clamp electrophysiology
and confocal microscopy. The biologically active 1α,25(OH)2-
vitamin D3 (1,25D) potentiates chloride and calcium channel
activities within minutes through mechanisms that involve sig-
nal transduction pathways and develop only in the presence of
a functional vitamin D receptor (4). Secretory activities are cou-
pled to 1,25D-activation of ion channels and elevation of cyto-
plasmic calcium, and lead to bone matrix production (7). Al-
though the primary focus of this review is on basic research,
the long-term objective of our work is to identify molecular tar-
gets in the treatment of bone pathologies characterized by de-
creased bone mass and mineralization. This typifies skeletal
diseases such as osteoporosis and osteomalacia, respectively.
Osteoporosis in particular affects a large sector of the aging
population and constitutes a significant financial burden for the
society.
Vitamin D and bone
Bone anabolic effects of 1,25D (8, 9) comprise matrix produc-
tion and mineralization (10). In osteoblasts, the bone-forming
cells, activation of bone matrix protein synthesis by 1,25D oc-
curs via the nuclear vitamin D receptor (VDR), which modu-
lates gene transcription (11, 12). In addition, 1,25D exerts non-
genomic effects in osteoblasts. Known as rapid actions, they
have been described for different steroids (13). Rapid actions
are characterized by: 1) developing within seconds to minutes,
which excludes the possibility of new mRNA and protein syn-
thesis; 2) insensitivity to inhibitors of gene transcription and
protein synthesis, and 3) appear in response to steroids bound
to large molecules such as BSA, which prevents them from en-
tering the cell. In osteoblasts, rapid non-genomic 1,25D actions
are characterized by: a) activation of intracellular signal trans-
duction pathways (14, 15), b) elevation of cytoplasmic Ca2+
concentration (16, 17), and c) potentiation of ion channel activi-
ties (2, 3, 18, 19). However, the physiological significance of
these rapid, membrane-initiated effects of 1,25D in bone cells
remains a field relatively unexplored.
It has been known for over a century that vitamin D deficiency
leads to rickets and osteomalacia, characterized by bone le-
sions and deformities from inadequate mineralization (20). In
addition, dietary calcium and vitamin D supplementation have
proven to be effective in the treatment of osteoporosis, a dis-
ease characterized by bone mass loss (21). A number of ef-
fects have been described when primary osteoblasts or os-
teoblastic cell lines are treated with 1,25D in vitro. By acting on
the VDR in the cell nucleus, 1,25D modulates the expression
of genes associated with osteoblast differentiation and bone
production, such as alkaline phosphatase (22), type I collagen,
and non-collagenous proteins (23-26). In addition, 1,25D stim-
ulates mineralization in cultures of osteoblast-like cell lines
(27). Some research groups postulate indirect effects of vita-
min D metabolites on bone formation, mainly centered around
the idea that 1,25D acts primarily on calcium intestinal absorp-
Non-genomic mechanisms of vitamin D-regulated bone
formation in osteoblasts
Mini-review
NON-GENOMIC_Zanello  13/06/2006  10.52  Pagina 50
tion and delivery of calcium to the bone (28, 29). In fact, the ef-
fect of 1,25D on bone in vivo appears to be a combination of
direct actions on bone cells (30) and indirect actions to regu-
late calcium absorption and delivery to the bone (31).
Non-genomic, rapid effects of 1,25D in osteoblasts
The study of membrane-initiated, non-genomic actions of
steroids in different cell systems has become a rapidly expand-
ing field of research in recent years. The idea of steroids exert-
ing a rapid effect at the cell membrane level was first formulat-
ed by Szego and collaborators several decades ago (32, 33).
However, the majority of our current knowledge on steroid
mechanisms of action resides mainly at the genomic level, with
relatively less research addressing rapid or non-genomic stud-
ies. Among different functions attributed to non-genomic ac-
tions of steroids are those that involve rapid ion movements
across the cell membrane and rapid membrane fusion as part
of secretory processes in different tissues involving cytoplas-
mic signaling pathways (34, 35). In osteoblasts, however, there
is no current consensus on how the non-genomic 1,25D signal-
ing cascade is initiated. Some groups propose that the VDR or
a slightly modified protein is responsible for initiating rapid re-
sponses (36); others propose the existence of a membrane-as-
sociated receptor of different molecular structure (31, 37). 
It has been shown that hormone 1,25D rapidly increases intra-
cellular Ca2+ in confluent mouse osteoblasts (16); 70% of this
response comes from external Ca2+ entering through Ca2+
channels in the plasma membrane, and 30% from Ca2+ re-
leased from the ER. In osteosarcoma ROS 17/2.8 cells, low
doses (0.1-1 nM) of 1,25D promote an acute, transient (1 min
long) rise in intracellular Ca2+ concentration in 40% of the cells
that is entirely dependent on extracellular Ca2+ (it is blocked by
Ca2+ channel blockers such as dihydropyridines). At higher
doses (over 1 nM), 1,25D-promotes an increase in intracellular
Ca2+ due to both the influx of extracellular Ca2+ and its release
from intracellular stores (38). Figure 1 shows the increase in
cytoplasmic Ca2+ concentration in a single live ROS 17/2.8 cell
1 min after the addition of 5 nM 1,25D to the bath. The Ca2+
signal lasted approximately 1 sec, and progressed inside the
cytoplasm in a wave fashion.
In addition, hormone 1,25D rapidly activates (sec-min) the
phosphatidylinositol (PI) cycle leading to formation of the sec-
ond messenger IP3 in mouse osteoblasts (14) and ROS 17/2.8
cells (38). Local intracellular Ca2+ elevation is crucial for the fu-
sion of secretory vesicles to the plasma membrane and exocy-
tosis (39). This occurs via activation of phospholipase C (PLC)-
β1 linked to a pertussis toxin (PTX)-insensitive G-protein (15,
40). IP3 promotes the release of Ca2+ from intracellular stores.
PLCs are effectors of different subunits of various G-proteins.
Several G-protein subunits (Gαq, Gαs, Gαi, Gβ and Gγ) have
been identified in female rat osteoblasts. It has been known
that the effect of 1,25D on IP3 formation and Ca2+ mobilization
in osteoblasts involves Gαq (40). 
1,25D effects on ion channels in osteoblasts
Steroids affect in different ways the activity of ion channels pre-
sent in the plasma membrane of target cells. Our studies
showed for the first time that physiological nanomolar concen-
trations of 1,25D increase outward Cl- currents in primary os-
teoblasts (4) and osteosarcoma ROS 17/2.8 cells (2, 3, 19)
within the first 5 minutes of treatment (see Figure 2A, B). This
1,25D-sensitive Cl- channel is a voltage-gated, volume-sensi-
tive anionic channel that activates upon depolarization (2). The
presence of different Cl- channel types in osteoblasts has been
demonstrated by means of electrophysiological studies. The
1,25D-sensitive Cl- channel that we characterized in ROS
17/2.8 cells and mouse calvarial osteoblasts shares some
electrical and pharmacological characteristics with a volume-
sensitive Cl- channel described by Gosling et al. (41, 42) and a
cAMP-activated Cl- channel found in primary osteoblasts (43).
It opens upon depolarization and is blocked by the specific Cl-
channel blocker DIDS in a time and voltage-dependent man-
ner. 
Chloride channels regulate a variety of physiological and cellu-
lar functions, including cell volume, electrical excitability, trans-
port of salts, and exocytosis (39). Most mammalian cells ex-
press members of the ClC gene family of voltage-gated chlo-
ride channels (44). The ClC gene family is composed of at
least nine members (ClC-1 through 7, ClC-Ka and Kb) present
in the plasma membrane or in the membranes of intracellular
compartments. The ClC protein structure has recently been re-
vealed by X-ray crystallography (45). To our knowledge, how-
ever, the molecular identity of Cl- channels expressed in os-
teoblasts remains unknown. Among these is the 1,25D-sensi-
tive Cl- channel. One possible candidate is the ClC-2 gene
(46). The ClC-2 is a broadly expressed channel that typically
activates by cell swelling and hyperpolarization (44). It has
been described in epithelial cells, and is involved in transport of
ions across epithelia, and cell volume regulation. The Cl- chan-
nel described by Gosling et al. (41) in ROS 17/2.4 cells acti-
vates in hyposmotic conditions. The 1,25D-sensitive Cl- chan-
nel that we described in the same osteoblastic cells is also a
volume-sensitive channel. However, 1,25D-potentiation of the
currents occurs also under isotonic conditions.
Another possible candidate for the 1,25D-sensitive Cl- channel
protein is the one encoded by the ClC-3 channel gene (47).
Figure 1 - 1,25D stimulated cytoplasmic calcium wave in a ROS 17/2.8 cell. Series of confocal microscope Ca2+ images obtained from a single cell af-
ter the addition of 5 nM 1,25D to the bath. Sequential images were obtained with a confocal fluorescence microscope every 0.33 sec. Cells were
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This channel is also expressed broadly, and seems to be mostly
associated with endosomal and synaptic membranes (44). It is
inhibited by DIDS and shows outward rectification, and in these
respects it resembles the osteoblast 1,25D-sensitive Cl- chan-
nel. On the other hand, there is a ClC-7 channel described in
osteoclasts. Mutation of this gene has been associated with se-
vere osteopetrosis in mice and humans (48). ClC-7 is present in
vesicle membranes in the osteoclast ruffled border, and thus
participates in acidic dissolution of the inorganic components of
the bone. There are no reports on ClC-7 in osteoblasts so far.
With these facts in mind, we searched for the expression of
ClC-2, ClC-3 and ClC-7 channel genes in the osteoblastic ROS
17/2.8 cell line by means of PCR amplification. As shown in Fig-
ure 2C, we found that the ClC-3 gene is expressed in the os-
teoblasts, which agrees with our electrical and pharmacological
characterization of the 1,25D-sensitive Cl- channel. 
Some cation channels activate within seconds-minutes with
physiological concentrations of 1,25D in osteoblasts. The best
known 1,25D-sensitive cation channel in osteoblasts is a high
voltage activated calcium channel shown in Figure 3. When
added to the bath, 1,25D causes a shift in the activation of
Ca2+ currents to more negative membrane potentials within the
first 5 sec (2, 3, 18). This is a dihydropyridine-sensitive, or L-
type Ca2+ (L-Ca) channel. The precise molecular mechanisms
of 1,25D effects on the osteoblast L-Ca channel remain un-
known. There is evidence that voltage-dependent L-Ca chan-
nels need to be phosphorylated to respond to membrane depo-
larization. Protein kinases A and C, cAMP, and GTP-binding
proteins are involved in the phosphorylation of Ca2+ channel
subtypes (see review, 49). In osteoblasts, we have shown that
cAMP mimicks 1,25D-promoted changes in voltage-activation
of the L-Ca channel (3). In addition, in muscle cells, 1,25D
rapidly activates L-Ca channels via a non-genomic mechanism
that involves a G protein-mediated stimulation of the adenylate
cyclase/cAMP/PKA messenger system (50).
Modulation of ion currents by 1,25D in ROS 17/2.8 cells 
occurs via intracellular signaling pathways
Stimulation of phosphorylation pathways in ROS 17/2.8 cells
mimics the effect of 1,25D on ion channel activities. There is pre-
52 Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 50-57
L.P. Zanello
Figure 2 - Effect of 1,25D on outward Cl- currents in ROS 17/2.8 cells.
A, Current to voltage (I/V) relations. Inward Ca2+ currents were record-
ed at the beginning of the experiment (closed circles). Subsequent ad-
dition of 0.05-5 nM 1,25D to the bath activated an outward Cl- current
(open symbols) within 2.5 min at depolarizing potentials. Increasing
concentrations of 1,25D (0.5 nM and 5 nM, open squares and triangles,
respectively) promoted increasingly larger outward Cl- currents over the
entire range of depolarizing potentials. Test voltages for I/V curves were
50 ms-long and ranged from 30 to 80 mV. Holding potential –70 mV.
B, Current traces corresponding to amplitude values depicted in A, for
control inward (Ca2+) currents before the addition of 1,25D, and 1,25D-
potentiated outward (Cl-) currents. C, Expression at the mRNA level of
the voltage-gated ClC-3 channel in ROS 17/2.8 cells cultured for 4
days. For RT-PCR experiments, we used templates designed from pre-
viously cloned rat Cl- channels (cDNA sequences were obtained from
GenBank). ROS 17/2.8 cells expressed the outward rectifier, DIDS-sen-
sitive ClC-3, but not the ubiquitous swelling-activated ClC-2. Transcripts
of the intracellular ClC-7 channel were also found, although in signifi-
cantly lower amounts. 
Figure 3 - Effect of 1,25D on inward Ca2+ currents in ROS 17/2.8 cells.
I/V relations obtained for L-Ca channels (A) before (closed circles) and
after (open symbols) the addition of 0.5 and 5 nM 1,25D to the bath.
Calcium currents were blocked by 100 μM CdCl2 added to the bath at
the end of the experiment. B, Current traces corresponding to ampli-
tude values depicted in A, for control Ca2+ currents before the addition
of 1,25D, and for 1,25D-potentiated L-Ca currents. Pulse protocols are
as in Figure 2 for 200 ms-long voltage pulses. [Duplicated with permis-
sion from (2)].
NON-GENOMIC_Zanello  13/06/2006  10.52  Pagina 52
Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 50-57 53
Non-genomic mechanisms of vitamin D-regulated bone formation in osteoblasts
vious evidence for modulation of L-Ca channels in osteoblasts
by cAMP associated with actions of the natural vitamin D
metabolite 24,25(OH)2-vitamin D3 and parathyroid hormone (51).
We found that the cell permeant cAMP analog diBucAMP poten-
tiates (about 2.5-fold at 0 mV) inward Ca2+ currents after 5 min in
a fashion clearly similar to hormone 1,25D, and causes a signifi-
cant shift in current to voltage relations to negative values (3).
This shift facilitates the opening of L-Ca channels at membrane
potentials close to the resting value, and promotes the influx of
Ca2+ ions from the extracellular medium.
In addition, we found that forskolin (20 mM), an adenylate cy-
clase activator, causes a significant Cl- current increase in 40%
of ROS 17/2.8 cells after 2 min. Pre-incubation of cells with
0.05 mM staurosporine, a broad spectrum PK inactivator, in-
hibited 1,25D-potentiation of Cl- currents (3). Taken together,
these results indicate that 1,25D appears to potentiate Cl-
channel functions in ROS 17/2.8 cells through phosphorylation
of the channel molecule via a cAMP/PKA pathway. 
It has been observed that, in general terms, steroids affect ion
channel activities through different mechanisms. Most studies
have shown steroid blocking effects at micromolar concentra-
tions (52-56). Our work in osteoblasts, however, uses nanomo-
lar, physiological concentrations of 1,25D. The hormone modu-
lates the voltage-sensitivity of L-Ca channels by shifting current
to voltage relations to more negative potentials (18), on one
hand, and increases the conductance of voltage-gated Cl-
channels, on the other (2, 3, 18). Our observations therefore
reveal multiple mechanisms of action of 1,25D on ion channel
activities that take place simultaneously in the osteoblast plas-
ma membrane. Table I summarizes 1,25D effects on ion chan-
nel types in ROS 17/2.8 cells, and the mechanisms of action
that we propose [extracted from (57)]. 
We recently reported that the VDR is necessary for rapid
1,25D-potentiation of Cl- and Ca2+ currents in osteoblasts.
Treatment with 5 nM 1,25D remarkably increased Cl- currents
within 1-5 min in cells expressing a functional VDR, but not in
osteoblasts isolated from a VDR KO mouse (see Figure 4) (4,
7). In addition, the hormone did not alter the voltage-sensitivity
of Ca2+ channels in VDR KO osteoblasts. To carry out these
studies, we used primary calvarial osteoblasts isolated from
neonatal VDR KO mice. We used the Tokyo VDR KO mice
generated by targeted ablation of exon 2 (58). VDR wild type
(WT) and knockout (KO) mice had been used previously to
characterize the physiological status caused by an abolished
vitamin D metabolism (59, 60). We detected the presence of
the VDR molecule by immunocytochemistry in ROS 17/2.8
cells with the use of a primary antibody against VDR and a
FITC-conjugated anti-mouse secondary antibody. Figure 5
shows that the VDR localizes abundantly in the cytoplasm and
in the proximity to the plasma membrane (61).
Figure 4 - 1,25D potentiation of Cl- currents in VDR WT but not in KO
osteoblasts. Fold increase (average ± S.D.) of whole-cell outward Cl-
currents promoted by the addition of 5 nM 1,25D. Current amplitudes
were measured at -80 mV from genotyped VDR +/+ (n = 6), +/- (n = 6),
and -/- (n = 11) mouse calvarial osteoblasts. [Duplicated with permis-
sion from (7)].
CHANNEL TYPE
1,25D EFFECTS
1,25D MODE OF ACTION
L-Ca
Shifts V-sensitivity (seconds)
Direct interaction and signal transduction
from a membrane-associated receptor
cAMP
Phosphorylation
VDR is necessary
Cl-
Increases conductance (minutes)
Signal transduction from a membrane-asso-
ciated receptor coupled to a PTX-insensitive
Gq protein
cAMP (40% of cells)
Phosphorylation (PK)
VDR is necessary
Table I - Summary of 1,25D effects on voltage-gated Ca2+ and Cl- channels in osteoblasts. V: voltage; PTX: Pertussis toxin.
Figure 5 - Subcellular localization of the VDR in ROS 17/2.8 cells. This
confocal immunofluorescence micrograph shows a strong signal in the
cell cytoplasm and portions of the plasma membrane region (arrow).
Bar = 40 μM.
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Ion channels and VDR play a role in exocytosis in osteoblasts
In excitable cells, Ca2+ channels function as transducers of an
electrical signal (action potential) into a chemical signal (exocy-
tosis of neurotransmitters). Osteoblasts, however, are non-ex-
citable cells, and 1,25D appears to act in lieu of action poten-
tials to facilitate the opening of Ca2+ channels, Ca2+ influx, and
an immediate exocytotic response (7). Recently, Cl- channels
have been shown to play a crucial role in exocytosis. Located
in the secretory vesicle membrane and the plasma membrane,
Cl- channels provide the electrical shunt for acidification of the
vesicle content by a H+-ATPase and loading of secretory pro-
teins. In β-pancreatic cells, for example, insulin secretion is
strongly inhibited by the stilbene derivative DIDS, and the ClC-
3 channel is localized in the secretory vesicle membrane (62).
Thus, 1,25D appears to modulate osteoblast exocytosis by act-
ing on the ion channels directly involved in the secretory
process. The 1,25D-sensitive L-Ca and Cl- channels are there-
fore likely to be the transducers of a hormonal signal into an
electric signal (local depolarization-repolarization) coupled to
secretion.
Osteoblasts produce new bone by secreting a complex extra-
cellular matrix that has the capacity to mineralize when ade-
quate amounts of calcium and phosphate are supplied. Bone
matrix proteins include type I collagen as the major compo-
nent, and proteoglycans, glycoproteins and gamma-carboxylat-
ed proteins. Osteoblasts express the protein components of
the SNARE complex involved in the docking of secretory vesi-
cles to the plasma membrane during regulated secretion (63).
Regulated secretion of proteins, which is typical of neurosecre-
tory, endocrine and exocrine cells, occurs as a rapid fusion of
vesicles docked to the plasma membrane in response to a
specific electrical or chemical stimulus. This is associated with
changes in the electrical state of the plasma membrane and el-
evation of cytoplasmic Ca2+ (39). On the other hand, constitu-
tive secretion of proteins had been traditionally associated with
osteoblast physiology until recently. This is a continuous
process controlled at the genomic level that comprises the pro-
duction, packing, shipping, and continuous release of secretory
products such as matrix proteins (64). Our recent finding of a
regulated type of secretion stimulated by a steroid in os-
teoblasts is a novel concept. The molecular mechanisms un-
derlying this secretion remain to be elucidated. 
Figure 6A shows the presence of secretory granules docked to
the plasma membrane of a single ROS 17/2.8 ostoeblast. SEM
images in Figures 6B, C show collagen fiber production by se-
cretory mechanisms in 8 day-old cultures. We found that
steroid-regulated secretion occurs in osteoblasts expressing a
functional VDR, but not in cells obtained from a KO VDR
mouse (58). Hormone 1,25D, by acting rapidly at the os-
teoblast plasma membrane level via interaction with a mem-
brane-associated VDR, promotes the release within seconds-
minutes of the secretory content -typically collagen- of mem-
brane-docked vesicles. The anabolic effects of the hormone in
bone can therefore be explained at both the genomic (synthe-
sis of proteins) and non-genomic (exocytosis of proteins) lev-
els. 
We demonstrated in osteoblasts that a rapid physiological re-
sponse to 1,25D is the activation of secretion (7). This happens
simultaneously with Cl- channel activation. We performed con-
tinuous recordings of whole-cell capacitance as a measure of
exocytosis in single cells (65). The addition of 1,25D to the ex-
ternal solution increased the frequency of individual exocytotic
events within the first 1-5 min only in osteoblasts isolated from
VDR wild type mice. Figure 7 shows typical capacitance re-
sponses to 1,25D obtained from a single live VDR WT os-
teoblast.
Figure 6 - Images of secretory vesicles (A) and associated secretory activities (B, C) in ROS 17/2.8 cells at early stages of bone formation. A, Secre-
tory vesicles (arrow in A) can be observed in close proximity to the plasma membrane. Cells were stained with 3 μM octadecyl rhodamine and ob-
served with confocal fluorescence microscopy. B, C: SEM images obtained from a 4-day old ROS 17/2.8 cell culture. Cells were treated with 5 nM
1,25D for 5 min before fixation with 2.5% glutaraldehyde in Na cacodylate buffer. In B, ROS 17/2.8 cells colony. In C, detail of the plasma membrane
surface of a ROS 17/2.8 cell at high magnification. Notice the presence of collagen fibers on the cell surface.
Figure 7 - 1,25D stimulation of exocytotic activities in osteoblasts.
Whole-cell capacitance recordings obtained from a single VDR WT os-
teoblast in the absence (top trace) and presence (bottom trace) of 5 nM
1,25D3 added to the bath. Upward deflections from an initial capaci-
tance value of 53.4 pF (dotted line) represent the fusion of individual
secretory granules to the osteoblast plasma membrane (exocytotic
events). Notice increased frequency of events obtained after hormone
addition (bottom trace). [Duplicated with permission from (7)].
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Summary model for non-genomic mechanisms of 1,25D
electrical effects in osteoblasts
Figure 8 summarizes our current hypothesis of the sequence
on molecular events that take place at the osteoblast cell mem-
brane and lead to rapid 1,25D electrical effects coupled to exo-
cytosis (3). Mechanical strain exerted on the cell surface is the
initial natural primary stimulus that activates stretch-activated
cation channels (SA-Cat) expressed in osteoblasts (66). Bones
are subjected to mechanical load due to gravity force and mus-
cle activity. This translates into movement of fluids within bone
trabeculae and a shear force applied to the osteoblast surface.
The influx of positive charges into the cytoplasm due to SA-Cat
channel activation and potentiation by 1,25D causes an initial,
local depolarization of the osteoblast membrane from -40 mV
at rest, to around 0 mV. This depolarization opens L-Ca chan-
nels at low positive membrane potentials. As we showed in our
research, calcium channel opening is potentiated at low depo-
larizing potentials by physiological concentrations of 1,25D (2).
Hormone binding to a membrane-associated receptor (possibly
VDR) appears to stimulate the production of cAMP via a Gq /
adenylate cyclase pathway. This in turn may activate PKA, and
ultimately the phosphorylation of L-Ca channels necessary for
channel opening. A local elevation of cytoplasmic Ca2+ concen-
tration near L-Ca channels promotes the fusion of secretory
vesicles to the plasma membrane, and release of secretory
contents into the extracellular medium. This local elevation of
cytoplasmic Ca2+ causes a further depolarization of the plasma
membrane to slightly positive values, which in turn promotes
the opening of Cl- channels. These Cl- channels are also po-
tentiated by 1,25D through similar VDR / Gq / PKA pathways.
The influx of Cl- ions into the cytoplasm contributes to the repo-
larization of the cell membrane to regenerate negative initial
values.
Conclusions
Our work addresses molecular mechanisms of bone formation
by investigating non-genomic effects of the steroid 1,25D in os-
teoblasts. The study of bone formation has traditionally focused
on understanding the control of bone cell proliferation, differenti-
ation and apoptosis by different metabolic agents with effects
on bone. From this viewpoint, bone formation during the
process of bone remodelling in the adult skeleton has been
evaluated as the result of an increased osteoblast relative to os-
teoclast activity (67, 68). Similar perspective has been applied
to the study of the pathophysiology of bone mass loss, in which
a disordered control of relative bone cell numbers – in osteo-
porosis, for example, too many osteoclasts relative to fewer os-
teoblasts – has been described (69). Therefore, the emphasis
of these studies has typically been at the bone tissue level.
By focusing at the single-cell level, our studies contribute to the
understanding of the molecular basis of bone diseases charac-
terized by decreased bone formation and mineralization, and
therefore to their treatment. These include osteoporosis, rick-
ets and osteomalacia. In particular, osteoporosis constitutes a
major financial burden for the American society, which will in-
crease in the near future owing to the extended life expectancy
of the population. Every possible effort including a full under-
standing of the molecular basis of these diseases should be
made to diminish the financial impact on society and to im-
prove the quality of life of those who suffer from these dis-
eases.
Experimental procedures
Cell culture. Osteosarcoma ROS 17/2.8 cells were cultured ac-
cording to previously published protocols (2). Briefly, ROS
17/2.8 cells (kindly provided by M.C. Farach-Carson, University
of Delaware) were grown in DMEM/Ham’s F-12 (50:50, v/v)
supplemented with 10% fetal bovine serum and antibiotics.
Cell cultures were kept in a humidified atmosphere containing
5% CO2 at 37°C. For patch-clamp experiments, cells were
used within the first 4 days after each passage. 
Primary osteoblast cultures were established from 3-5 day old
mouse calvaria as published before (4). Stripped parietal
bones were fragmented (~1 mm2), washed several times in
sterile HEPES buffer, and transferred to 35 mm Falcon culture
dishes. Typically, osteoblasts migrated from the bone frag-
ments and settled on the bottom of culture dishes after 1-2
days. Mature osteoblasts showing a typical polyhedral shape
were used for patch-clamp recordings within the first 2-4 weeks
in culture. 
Vertebrate animals. We used the Tokyo VDR KO mice generat-
ed by targeted ablation of exon 2 at the University of Tokyo, and
kindly provided by S. Kato (58). Heterozygous (+/-) mice were
bred to generate (-/-) homozygous VDR KO mice, which were
raised on a normal diet. Wild type heterozygous (+/-) and ho-
mozygous (+/+) siblings were used as controls. Animals were
genotyped using a 1-cm tail sample at 21-30 days of age. New-
born and adult mice were euthanized by decapitation and cervi-
cal dislocation, respectively, to isolate calvaria. Primary cells
from bone samples were kept in culture for up to 2 months. 
Electrophysiology. Whole-cell patch-clamp recordings (70)
were performed with a HEKA EPC-9 amplifier (ALA Scientific
Instruments Inc., Westbury, NY) on individual osteoblasts.
Patch pipettes of about 2 MΩ were fabricated with a DMZ Uni-
versal micropipette puller from Drummond capillaries (Drum-
mond Scientific Co., Broomall, PA), coated with Sylgard elas-
tomer (Dow Corning Corp., Midland, MI) to reduce capacitative
transients, and fire-polished. Ion channel activities were
recorded in a bath (external) solution composed of (in mM):
150 TEA-Cl, 3.1 KCl, 20 BaCl2, 1 MgCl2, 4 NaHCO3, 10 Hep-
es, 20 sucrose, pH 7.4 (adjusted with TEA-OH). The pipette
(internal) solution consisted of (in mM): 150 CsCl, 15 NaCl, 4
MgCl2, 5 EGTA, 10 HEPES, pH 7.4 (adjusted with NaOH). 
Whole-cell capacitance values were measured using the soft-
ware-based lock-in implementation of Pulse (v.8, HEKA EPC-
9). We applied a sine wave with a frequency of 500 Hz and
peak amplitude of 20 mV, which was superimposed on a hold-
Figure 8 - 1,25D non-genomic signaling pathways in osteoblasts. The
scheme summarizes 1,25D membrane-initiated pathways overviewed
in this paper. The explanation is given in the text.
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ing potential of 0 mV. Whole-cell capacitance was continuously
monitored for 10-20 min, sampling every 0.1-1 sec. 
Microscopy. Rat osteosarcoma ROS 17/2.8 cells were cultured
on cover slips in 35 mm Petri-dishes for 48 hours. Cytoplasmic
calcium signals were visualized in live, single osteoblasts with
a laser scanning confocal Leica TCS SP2 Microscope (Leica
Microsystems, Inc., Exton, PA). Cells were loaded with the cal-
cium sensitive dye Fluo 3-AM (5 μM, Molecular Probes), for 30
min at 30°C. The raise in cytoplasmic Ca2+ concentration was
detected as an increase in fluorescence intensity 1-3 min after
the addition of 5 nM 1,25D to the bath.
For immunocytochemistry observations, ROS 17/2.8 cells were
fixed with 3.7% (v/v) formaldehyde at room temperature for 20
min, and permeabilized with ice-cold ethanol for 5 min. We
used a primary antibody against VDR (D-6, Santa Cruz
Biotechnology CA) and a FITC-conjugated anti-mouse sec-
ondary antibody (Sigma Immunochemicals St. Louis, MO). Im-
munostaining was visualized with an Olympus IX50 inverted
fluorescence microscope. For SEM observations, cells were
grown on glass cover slips for 5 days and fixed with 4% forma-
lin (Sigma) in 0.1 M Na cacodylate buffer, for 1 hour at room
temperature. Coverslips were then washed 3 times with 0.1 M
sodium cacodylate. Samples were incubated with 1% osmium
tetroxide in the same buffer, for 1 hour at room temperature.
Dehydration was performed in an ethanol series (30%, 50%,
70%, 80%, 95%, and 100%), and samples were critical point
dried. Samples were then covered by a thin gold/palladium lay-
er, and observed on a Philips SEM XL-30 microscope.
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